Target intelligence / Profile preview

GTF3C2 antisense RNA 1 (GTF3C2-AS1)

Target
GTF3C2-AS1
Molecular classification
Long non-coding RNA (lncRNA), Non-coding RNA, Other
01

Overview

GTF3C2 antisense RNA 1 (GTF3C2-AS1) is a long non-coding RNA gene located on chromosome 2, functioning as an antisense transcript to the General Transcription Factor IIIC Subunit 2 (GTF3C2). Non-coding RNAs like GTF3C2-AS1 do not produce proteins but modulate gene expression, often by interacting with protein complexes or through epigenetic regulation. GTF3C2-AS1 has been implicated in transcriptional regulation, cell growth, and proliferation. Recent studies identify GTF3C2-AS1 as a member of prognostic lncRNA panels capable of stratifying endometrial cancer patients by survival risk, making it a potential molecular marker for cancer prognosis. However, its specific biological roles and mechanisms remain under-researched, with no direct evidence for use as a therapeutic target or known drug interactions. GTF3C2-AS1 stands as a candidate biomarker and regulatory molecule within cancer biology, with further research needed to fully elucidate its contributions to gene regulation and disease

Other names
GTF3C2-AS1GTF3C2 antisense RNA 1ENSG00000234945NCBI Gene ID: 100505624HGNC: 40269
02

Mechanism of action

None defined. No mechanisms of action for drugs against GTF3C2-AS1, as it is not currently a drug target.

03

Biological functions

Transcriptional regulationCellular growth and proliferationPotential involvement in cancer/tumorigenesis
04

Disease associations

Cancer
05

Safety considerations

None reported in the context of therapeutic targeting, as GTF3C2-AS1 is not targeted by drugs. If considered for future therapeutic intervention (e.g., as part of antisense oligonucleotide strategies), generic lncRNA targeting concerns such as off-target effects and immune activation would theoretically apply.
06

Interacting drugs

None known
07

Biomarkers

Prognostic biomarker in endometrial cancer, used to stratify risk and predict survival outcomes as part of multi-lncRNA signatures

Beyond the preview

Go deeper on GTF3C2 antisense RNA 1 (GTF3C2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTF3C2 antisense RNA 1 (GTF3C2-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call